Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma (RRMM). Here, we report the final analysis of efficacy and safety from COLUMBA...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmani, Saad Z., Nahi, Hareth, Legiec, Wojciech, Grosicki, Sebastian, Vorobyev, Vladimir, Spicka, Ivan, Hungria, Vania, Korenkova, Sibirina, Bahlis, Nizar J., Flogegard, Max, Bladé, Joan, Moreau, Philippe, Kaiser, Martin, Iida, Shinsuke, Laubach, Jacob, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Lantz, Kristen, O’Rourke, Lisa, Heuck, Christoph, Delioukina, Maria, Qin, Xiang, Nnane, Ivo, Qi, Ming, Mateos, Maria-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521240/
https://www.ncbi.nlm.nih.gov/pubmed/35354247
http://dx.doi.org/10.3324/haematol.2021.279459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521240/
https://www.ncbi.nlm.nih.gov/pubmed/35354247
http://dx.doi.org/10.3324/haematol.2021.279459

Ejemplares similares